Press

Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Mar 8 • 3 min read

Toronto, Ontario–(Newsfile Corp. – March 8, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company“), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the…

The UAE Is Exploring the Rollout of Psychedelic Assisted Therapies

Mar 7 • 3 min read

The Energia Foundation and Tabula Rasa Ventures, notable for introducing psychedelic education at Davos in 2022, have been at the forefront of bringing understanding of psychedelic-assisted therapy to the Arabian Gulf. Their efforts over the past 14 months have focused on educating policymakers, sovereign wealth funds, and clinicians in the UAE about the benefits of psychedelic therapies. “Our work here…

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Mar 7 • 7 min read

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). The Company also announced that its Phase…

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomized Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

Mar 5 • 4 min read

VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio“) is pleased to announce final regulatory approvals have been received for a world’s first Phase 2B randomized controlled take home clinical trial microdosing MB22001 in patients with Major Depressive Disorder. The trial has received Ethics approval, has been approved…

Mushrooms Inc. (OTC:MSRM) Launches New Health Supplements, Progresses with German Partnership, and Boosts Engagement Initiatives

Mar 5 • 4 min read

ESTERO, Fla., March 05, 2024 (GLOBE NEWSWIRE) — via IBN — Mushrooms Inc., (OTC: MSRM) a developing leader in biotechnology and sustainable healthcare innovation using mushrooms and mycelium, is excited to announce a suite of strategic initiatives aimed at transforming the healthcare landscape. These initiatives include the launch of two groundbreaking health supplements, LONGEVITY and SPORT+, and the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441